Basics Akebia Therapeutics, Inc. Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. IPO Date: March 24, 2018 Sector: Healthcare Industry: Biotech Market Cap: $408.66M Activated in VL: True Average Daily Range Avg Daily Range: $0.13 | 3.52% Avg Daily Range (30 D): $0.06 | 3.10% Avg Daily Range (90 D): $0.07 | 2.75% Institutional Daily Volume Avg Daily Volume: 2.72M Avg Daily Volume (30 D): 4.87M Avg Daily Volume (90 D): 3.59M Trade Size Avg Trade Size (Sh.): 305 Avg Trade Size (Sh.) (30 D): 358 Avg Trade Size (Sh.) (90 D): 278 Institutional Trades Total Inst.Trades: 1,010 Avg Inst. Trade: $1.63M Avg Inst. Trade (30 D): $1M Avg Inst. Trade (90 D): $1.35M Avg Inst. Trade Volume: .47M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $1.56M Avg Closing Trade (30 D): $.96M Avg Closing Trade (90 D): $1.41M Avg Closing Volume: 465.96K     News Dec 1, 2025 @ 2:43 PM Why Is Small-Cap Q32 Bio Stock Soaring On Monday? Source: Vandana Singh Nov 6, 2025 @ 11:30 PM Vafseo® (vadadustat) Dialysis Dependent Patient... Source: Akebia Therapeutics Jul 8, 2025 @ 12:00 PM Akebia Therapeutics to Present at the H.C. Wainwri... Source: Mercedes Carrasco Jun 16, 2025 @ 10:00 AM AVEROA receives European marketing authorization f... Source: N/A May 28, 2025 @ 12:00 PM Akebia Therapeutics to Present at the Jefferies Gl... Source: N/A Financials   TTM Q3 2025 Q2 2025 Basic EPS $-.08 $ $ Diluted EPS $-.08 $ $ Revenue $ 225.07M $ 58.77M $ 62.47M Gross Profit $ 177.78M $ 49.38M $ 52.55M Net Income / Loss $ -15.91M $ .54M $ .25M Operating Income / Loss $ 17.75M $ 4.45M $ 14.09M Cost of Revenue $ 47.29M $ 9.38M $ 9.92M Net Cash Flow $ 132.45M $ 29.14M $ 23.94M PE Ratio